TrialCancer biology & therapy2023

Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.

Aihua Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.